Key result
Continuation of anticoagulation is generally safe for cataract and strabismus surgeries, while management for glaucoma, vitreoretinal, and oculoplastic surgeries should be individualized based on bleeding and thromboembolic risks.
Why the study?
Anticoagulant use is increasing among ophthalmic surgery patients, but decisions regarding discontinuation are nuanced and studies remain divided across non-cataract ocular surgeries.
Does the continuation of anticoagulants increase bleeding complications in patients undergoing ophthalmic surgery?
Does the continuation of anticoagulants increase bleeding complications in patients undergoing ophthalmic surgery?
Answers are grounded in this paper and cite their sources.
This review provides guidance on balancing thromboembolic and bleeding risks when managing anticoagulants perioperatively for various ocular surgeries.
Use of anticoagulant therapy has increased in patients presenting for ophthalmic surgery over the past decade. The decision of whether or not to discontinue anticoagulant medications prior to ophthalmic surgeries is nuanced and ultimately based on multiple factors including the type of surgery and the patient’s comorbidities and risk profile. In the setting of cataract surgery, no increased risk of bleeding with anticoagulation was observed in a large prospective study, which suggests that anticoagulation should not be interrupted for the average-risk patient on anticoagulation. In other types of ophthalmic surgery, expert opinion and studies are divided on the perioperative management of anticoagulant therapy. Preoperative thromboembolic risk stratification, intraoperative techniques to minimize bleeding, and postoperative management are also reviewed to generate more comprehensive recommendations on ophthalmic perioperative management of anticoagulation.
No takes yet. Share an insight, caveat, or question.
He et al. (2020) conducted a review in Ophthalmic surgery in patients on anticoagulant therapy. Perioperative continuation vs discontinuation of anticoagulants was evaluated on Bleeding and thromboembolic complications. Continuation of anticoagulation is generally safe for cataract and strabismus surgeries, while management for glaucoma, vitreoretinal, and oculoplastic surgeries should be individualized based on bleeding and thromboembolic risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: